Free Trial

ASLAN Pharmaceuticals (ASLN) Competitors

$0.70
-0.41 (-36.94%)
(As of 07/17/2024 ET)

ASLN vs. SNPX, LIXT, DRUG, PCSA, OGEN, MYNZ, MBIO, EVOK, HOTH, and AIMD

Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Synaptogenix (SNPX), Lixte Biotechnology (LIXT), Bright Minds Biosciences (DRUG), Processa Pharmaceuticals (PCSA), Oragenics (OGEN), Mainz Biomed (MYNZ), Mustang Bio (MBIO), Evoke Pharma (EVOK), Hoth Therapeutics (HOTH), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.

ASLAN Pharmaceuticals vs.

Synaptogenix (NASDAQ:SNPX) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.

In the previous week, ASLAN Pharmaceuticals had 2 more articles in the media than Synaptogenix. MarketBeat recorded 5 mentions for ASLAN Pharmaceuticals and 3 mentions for Synaptogenix. ASLAN Pharmaceuticals' average media sentiment score of 1.29 beat Synaptogenix's score of 1.08 indicating that Synaptogenix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Synaptogenix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ASLAN Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Synaptogenix presently has a consensus price target of $14.00, suggesting a potential upside of 212.50%. ASLAN Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 12,854.23%. Given Synaptogenix's higher probable upside, analysts plainly believe ASLAN Pharmaceuticals is more favorable than Synaptogenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synaptogenix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

ASLAN Pharmaceuticals received 198 more outperform votes than Synaptogenix when rated by MarketBeat users. However, 66.67% of users gave Synaptogenix an outperform vote while only 63.49% of users gave ASLAN Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
SynaptogenixOutperform Votes
2
66.67%
Underperform Votes
1
33.33%
ASLAN PharmaceuticalsOutperform Votes
200
63.49%
Underperform Votes
115
36.51%

Synaptogenix has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynaptogenixN/AN/A-$6.04MN/AN/A
ASLAN Pharmaceuticals$12M0.12-$44.22M-$21.92-0.03

ASLAN Pharmaceuticals' return on equity of -18.51% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -18.51% -14.36%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Synaptogenix has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 4.3% of Synaptogenix shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ASLAN Pharmaceuticals beats Synaptogenix on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASLN vs. The Competition

MetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.43M$7.21B$5.30B$8.52B
Dividend YieldN/A2.75%2.76%4.02%
P/E Ratio-0.0319.70134.4218.44
Price / Sales0.12483.052,253.07106.76
Price / CashN/A33.3235.3833.66
Price / Book-0.115.934.984.55
Net Income-$44.22M$147.02M$110.54M$216.32M
7 Day Performance-69.44%6.28%5.38%5.83%
1 Month Performance-75.70%8.23%8.10%7.15%
1 Year Performance-96.89%-1.57%6.29%3.50%

ASLAN Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNPX
Synaptogenix
2.6507 of 5 stars
2.65 / 5 stars
$4.50
+1.4%
$14.00
+211.1%
-80.9%$5.54MN/A0.005Positive News
Gap Down
LIXT
Lixte Biotechnology
0 of 5 stars
0.00 / 5 stars
$2.40
+1.3%
N/A-68.8%$5.40MN/A-1.034Positive News
DRUG
Bright Minds Biosciences
0 of 5 stars
0.00 / 5 stars
$1.20
-3.8%
N/A-70.5%$5.33MN/A-1.19N/APositive News
PCSA
Processa Pharmaceuticals
3.7888 of 5 stars
3.79 / 5 stars
$1.80
+2.9%
$8.00
+344.4%
-82.4%$5.15MN/A-0.3613Positive News
Gap Up
OGEN
Oragenics
0 of 5 stars
0.00 / 5 stars
$1.13
flat
N/A-69.5%$5.06M$40,000.00-0.135
MYNZ
Mainz Biomed
1.1959 of 5 stars
1.20 / 5 stars
$0.42
-1.8%
$6.00
+1,328.6%
-90.7%$5.04M$895,479.00-0.2665Gap Down
MBIO
Mustang Bio
1.6032 of 5 stars
1.60 / 5 stars
$0.40
-2.2%
$12.00
+2,931.8%
-93.1%$4.96MN/A-0.0980
EVOK
Evoke Pharma
0 of 5 stars
0.00 / 5 stars
$0.57
-3.4%
N/A-66.5%$4.91M$5.18M-0.314Analyst Forecast
Positive News
HOTH
Hoth Therapeutics
3.0854 of 5 stars
3.09 / 5 stars
$0.91
-2.2%
$4.00
+339.6%
-63.7%$4.88MN/A-0.474Positive News
AIMD
Ainos
0 of 5 stars
0.00 / 5 stars
$0.75
+0.2%
N/AN/A$4.88M$120,000.000.0040

Related Companies and Tools

This page (NASDAQ:ASLN) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners